Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial

Bibliographic Details
Main Authors: Ruth Wester, Sonja Zweegman, Bronno van der Holt, Marie José Kersten, Edo Vellenga, Marinus van Marwijk-Kooy, Emelie Asselbergs, Okke de Weerdt, Monique C. Minnema, Sarah Lonergan, Antonio Palumbo, Annemiek Broijl, Pieter Sonneveld
Format: Article
Language:English
Published: Wolters Kluwer 2020-08-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000370

Internet

http://journals.lww.com/10.1097/HS9.0000000000000370

Similar Items